Clinical Trial Update: Phase II Trial of Sacituzumab Govitecan in Recurrent and/or Metastatic Secretory Gland Cancers [Phase 2]

View source ↗

Summary

Phase II study of sacituzumab govitecan for recurrent/metastatic salivary gland cancer is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Salivary Gland Cancer

Drugs mentioned

• TRODELVY (sacituzumab govitecan)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Gland, Salivary Gland Cancers | Phase 2 | Status: RECRUITING